TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04326075

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP treatment
Description: CPAP should be performed as soon as possible and only with a helmet, using a positive end-expiratory pressure (PEEP) between 8 and 14 cmH2O and an inspired oxygen fraction (FiO2) between 40 and 60%.
Study: NCT03853343

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Seaweed extract
Description: 1 capsule 3 times per day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule 3 times per day
Study: NCT00452478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate
Description: 2250mg/day starting dose of lanthanum carbonate administered orally, in divided doses, with meals (500mg 750mg and 1000mg strengths)for 2 weeks; dose titration will occur based on serum phosphorus results not to exceed 3000mg/day.
Study: NCT03881254

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Offloading
Description: Patient will be offloaded in a diabetic camboot after treatment, or total contact cast if patient cannot be fit with diabetic offloading boot

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Offloading
Description: Patient will be offloaded in a diabetic camboot after treatment, or total contact cast if patient cannot be fit with diabetic offloading boot

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fibracol Wound Dressing
Description: Application of Collagen Alginate Dressing
Study: NCT01743729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lifitegrast
Description: Lifitegrast Ophthalmic Solution 5.0%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for Lifitegrast Ophthalmic Solution 5.0%
Study: NCT03742219

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Modification
Description: 1. Community awareness: a) individuals will be made aware of their own chronic lifestyle diseases and risk factors b) communities will be made aware of their aggregated data concerning chronic lifestyle related diseases and risk factors.~2. Education for individuals and communities on the meaning of the lifestyle diseases and risk factors. a) individual and small group sessions explaining diseases and lifestyle measures that are helpful, b) community level education to tentatively include i) shopping guides and recipes, ii) urban gardening projects, iii) puppet shows and other community presentations, iv) literature and posters.
Study: NCT03850665

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct Anterior Approach (DAA)
Description: Direct Anterior Approach surgery to replace the hip.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct Anterior Approach (DAA)
Description: Direct Anterior Approach surgery to replace the hip.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct Anterior Approach (DAA)
Description: Direct Anterior Approach surgery to replace the hip.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anterolateral approach
Description: Anterolateral approach surgery to replace the hip.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anterolateral approach
Description: Anterolateral approach surgery to replace the hip.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anterolateral approach
Description: Anterolateral approach surgery to replace the hip.
Study: NCT01527318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fibrate treatment
Description: Patients will receive a dosage of 400mg Bezafibrate every day during 28 weeks
Study: NCT01147172

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Elevess
Description: Injectable gel, 0.5mL or 1.0mL material supplied in a 1.0mL pre-filled sterile glass syringe with two 30 gauge needles
Study: NCT04048122

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MultiContext for PD Strategy Training
Description: This treatment is task-oriented training, a widely-used approach in neurorehabilitation, that parallels the cognitive process training used in PD to-date but with simulated functional tasks (vs. computer or paper \& pencil tasks). It has the same basic protocol as MC4PD, but it is therapist-directed, and the OT does not address strategies, metacognition, generalization, or use mediation or action plans. The OT selects treatment activities based on the client's cognitive profile and goals from a published set of activities designed for use in cognitive interventions. Graded task practice with OT feedback on performance accuracy is used to produce neurocognitive improvement (or possibly independent strategy development). The OT assigns practice of specific cognitively challenging everyday life activities for homework (but without action plans).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: This treatment is task-oriented training, a widely-used approach in neurorehabilitation, that parallels the cognitive process training used in PD to-date but with simulated functional tasks (vs. computer or paper \& pencil tasks). It has the same basic protocol as MC4PD, but it is therapist-directed, and the OT does not address strategies, metacognition, generalization, or use mediation or action plans. Therefore, this is a standard-of-care approach that includes all but the proposed critical elements of MC4PD. The OT reviews pre-treatment cognitive test scores with the client but without discussion to build awareness. The OT selects treatment activities based on the client's cognitive profile and goals from a published set of activities designed for use in cognitive interventions.
Study: NCT03576365

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VOICE Intervention Arm
Description: Introductory and background information about voice problems and psychosocial distress~* Examples of concerns raised by patients with voice problems (e.g., I feel left out of conversations because of my voice problem)~* Information about perceived control and how improving perceived control can lead to decreased distress~* Examples of strategies that have helped patients identify controllable and uncontrollable aspects of their voice problems (e.g., I learned to plan to take breaks to rest my voice between teaching classes)~* Self-guided exercises designed to help improve perceived control and develop better management skills for voice problem symptoms

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Information-Only Arm
Description: General introduction of the program and background on voice related information in an interactive manner~* Examples of what patients want to learn more about the voice (e.g., I would like to learn more about how the voice works when it is healthy)~* Information on the anatomy of the voice and how the voice works~* Educational materials to help understand voice physiology and function~* Self-guided learning exercises (e.g., what are some things about vocal function that you would like to learn more about?)
Study: NCT03182062

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Alveolar recruitment maneuver
Description: To start the Alveolar Recruitment Maneuver (ARM) the ventilatory mode will be changed to pressure-controlled mode (PCV) with 20 cmH2O pressure control ventilation. A respiratory rate (RR) of 15 rpm, inspiration: expiration ratio of 1:1, FiO2 of 0.8 and PEEP of 5 cmH2O. The PEEP level will be increased in 5 cmH2O steps every 10 respiratory cycles, increasing to 15 cycles in the last level of PEEP (20 cmH2O), getting an opening pressure at 40 cmH2O airway (duration of the maneuver: 160 sec.)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PEEP Titration Trial
Description: The ventilation mode will then switch back to volume controlled ventilation with the same baseline settings but with 20 cmH2O PEEP level. Then PEEP will be reduced in 2 cmH2O steps each maintained for 5 breaths the level of PEEP with the best (higher) dynamic compliance.
Study: NCT01086930

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: All participants will continue to receive the same standard care for the hand and upper limb as typically provided by their rehabilitation units.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Care
Description: All participants will continue to receive the same standard care for the hand and upper limb as typically provided by their rehabilitation units.
Study: NCT03038568

Intervention type: DIAGNOSTIC_TEST
Intervention: CT scan
Description: Patients with colorectal liver metastases scheduled for abdominopelvic CECT will be consented to undergo an additional CT of their abdomen (termed add-on CT) within 15 seconds, before or after, their clinical portal venous phase CT (PV CT), which is performed at a fixed delay of 80 seconds at our institution.
Study: NCT03182062

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lung protective ventilation
Description: Ventilatory strategy with a PEEP level of 5 cmH2O but without recruitment maneuvers and PEEP titration trial.
Study: NCT01724411

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistant Starch type 3
Description: Resistant Starch 3: 26g/day males for 11 days, 22 g/day females for 11 days
Study: NCT03318393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Description: Continuous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Unfractionated heparin
Description: Continuous infusion
Study: NCT00626951

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LMA Supreme
Description: Extraglottic airway devices

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LMA ProSeal
Study: NCT01066910

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral treatment for childhood obesity
Description: Behavioral treatment for childhood obesity includes nutrition and physical activity recommendations, and behavior therapy skills for parent and child.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral treatment for childhood obesity
Description: Behavioral treatment for childhood obesity includes nutrition and physical activity recommendations, and behavior therapy skills for parent and child.
Study: NCT03209765

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: WhatsApp reminder
Description: An interactive WhatsApp reminder to return to the centre for taking faecal tubes for screening
Study: NCT05490771

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib Hydrochloride
Description: Given IV
Study: NCT00970177

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent A/H1N1 influenza vaccine
Description: This trial will be performed at multiple study sites in a population of healthy adults and elderly. Subjects will be randomized to receive two IM injections of low dose of antigen \& adjuvant, or high dose of antigen \& adjuvant, or high dose of antigen, according to the study groups.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent A/H1N1 influenza vaccine
Description: This trial will be performed at multiple study sites in a population of healthy adults and elderly. Subjects will be randomized to receive two IM injections of low dose of antigen \& adjuvant, or high dose of antigen \& adjuvant, or high dose of antigen, according to the study groups.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent A/H1N1 influenza vaccine
Description: This trial will be performed at multiple study sites in a population of healthy adults and elderly. Subjects will be randomized to receive two IM injections of low dose of antigen \& adjuvant, or high dose of antigen \& adjuvant, or high dose of antigen, according to the study groups.
Study: NCT05490771

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT01736020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: A low dose of dexmedetomidine is used during scanning after dose piloting outside the scanner for memory effects and tolerability.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexmedetomidine
Description: A low dose of dexmedetomidine is used during scanning after dose piloting outside the scanner for memory effects and tolerability.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol
Description: A low dose of propofol is used during scanning after dose piloting outside the scanner for memory effects and tolerability.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: A low dose of propofol is used during scanning after dose piloting outside the scanner for memory effects and tolerability.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: A low dose of ketamine is used during scanning after dose piloting outside the scanner for memory effects and tolerability.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketamine
Description: A low dose of ketamine is used during scanning after dose piloting outside the scanner for memory effects and tolerability.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous Oxide
Description: A low dose of nitrous oxide is used during scanning after dose piloting outside the scanner for memory effects and tolerability.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nitrous Oxide
Description: A low dose of nitrous oxide is used during scanning after dose piloting outside the scanner for memory effects and tolerability.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05115578

Intervention type: DRUG
Intervention: Remifentanil 1 MG Injection [Ultiva]
Description: Group I TCI effect-site target infusion of 1.5 ng/ml of remifentanil.

Intervention type: DRUG
Intervention: Remifentanil 1 MG Injection [Ultiva]
Description: Group I TCI effect-site target infusion of 1.5 ng/ml of remifentanil.
Study: NCT01021332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg)
Description: oral
Study: NCT05115578

Intervention type: DRUG
Intervention: Midazolam 1 MG/ML Prefilled Syringe
Description: Group II TCI effect-site target infusion of 1.5 ng/ml of remifentanil + 1 mg Midazolam iv

Intervention type: DRUG
Intervention: Saline solution
Description: Group III Control
Study: NCT01021332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/9 mg)
Description: oral
Study: NCT05115578

Intervention type: DEVICE
Intervention: Algometry
Description: The algometry technique is used to assess the pain pressure threshold as an analgesic effect of remifentanil concerning Minto's model prediction.

Intervention type: DEVICE
Intervention: Algometry
Description: The algometry technique is used to assess the pain pressure threshold as an analgesic effect of remifentanil concerning Minto's model prediction.

Intervention type: DEVICE
Intervention: Algometry
Description: The algometry technique is used to assess the pain pressure threshold as an analgesic effect of remifentanil concerning Minto's model prediction.
Study: NCT01069627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 15 mg/kg intravenously on day 1 of every 3 week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fotemustine
Description: 100 mg/m² intravenously on Days 1, 8, and 15, followed by 4 weeks of rest, then every 21 days up to 4 to 6 cycles
Study: NCT01959386

Intervention type: DRUG
Intervention: Trastuzumab
Description: Participants will be receiving trastuzumab as part of their treatment for breast cancer according to the judgement of physician and according to the actual summary of product characteristics. The study protocol does not influence the physician's decision regarding diagnostics, therapy or frequency of medical examination during or after the treatment.
Study: NCT04771884

Intervention type: DRUG
Intervention: meropenem vancomycin ceftazidime ceftriaxone ceftizoxime linezolid
Description: The use of antimicrobial agents depends on the clinical practice
Study: NCT02396251

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HA experimental

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HA experimental

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HA comparator
Study: NCT03740867

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation
Description: Exercise program includes aerobic (walking band, bicycle, arm ergometer) and strengthening (with free weights) components.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation
Description: Exercise program includes aerobic (walking band, bicycle, arm ergometer) and strengthening (with free weights) components.
Study: NCT02210468

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: APIC-CF, 4 cc

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: APIC-CF, 2 cc

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Saline
Description: Placebo Comparator: Saline
Study: NCT00521612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sevoflurane
Description: Volatile anaesthetic sevoflurane 1 MAC (2,0 vol%) will be administer to the patients in the form of gas (via respiration). First 20 minutes of anaesthesia will be period of saturation of the body with anaesthetic sevoflurane. After 20 minutes the depth of anaesthesia will be titrated with level of anaesthetic sevoflurane. Change will be +10 % of sevoflurane MAC (0,2 vol%) for every change of signs that indicate shallow anaesthesia. Change will be -10 % of sevoflurane MAC (0,2 vol%) for every change of signs that indicate too deep anaesthesia. Measuring points will be every 5 minutes during surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: isoflurane
Description: Volatile anaesthetic isoflurane 1 MAC (1,2 vol%) will be administer to the patients in the form of gas (via respiration). First 20 minutes of anaesthesia will be period of saturation of the body with anaesthetic isoflurane. After 20 minutes the depth of anaesthesia will be titrated with level of anaesthetic isoflurane. Change will be +10 % of isoflurane MAC (0,12 vol%) for every change of signs that indicate shallow anaesthesia. Change will be -10 % of isoflurane MAC (0,12 vol%) for every change of signs that indicate too deep anaesthesia. Measuring points will be every 5 minutes during surgery.
Study: NCT02867085

Intervention type: OTHER
Intervention: Observational
Description: The BoHemE study does not provide any recommendations for treatment. Guidelines for osteoporosis treatment and standardized instructions for MDS patients are available, however the choice of treatment is up to the treating physician and should be reported as such.

Intervention type: OTHER
Intervention: Observational
Description: The BoHemE study does not provide any recommendations for treatment. Guidelines for osteoporosis treatment and standardized instructions for MDS patients are available, however the choice of treatment is up to the treating physician and should be reported as such.
Study: NCT03041532

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Proximal retroflexion
Description: The investigator explore twice right colon, first front view and second forward viewing or proximal retroflexion depends on randomization

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Frontal view
Description: The investigator explore twice right colon with frontal viewing

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Frontal view
Description: The investigator explore twice right colon with frontal viewing
Study: NCT04415047

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JenaValve Trilogy Heart Valve System
Description: TAVR with JenaValve Trilogy Heart Valve System
Study: NCT04692857

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: supra inguinal fascia iliaca block
Description: injection of 30,40 or 50 ml of 0.2 ropivacaine .

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: supra inguinal fascia iliaca block
Description: injection of 30,40 or 50 ml of 0.2 ropivacaine .

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: supra inguinal fascia iliaca block
Description: injection of 30,40 or 50 ml of 0.2 ropivacaine .
Study: NCT01685216

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: velaglucerase alfa
Description: lyophilized powder, intravenous infusion, units, Every other week (EOW)
Study: NCT01142908

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmacist CVD
Description: clinical pharmacist-administered intervention which focuses on behavioral and medication management for 12 months.
Study: NCT04573309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1840
Description: Administered orally as tablets.
Study: NCT02874287

Intervention type: DRUG
Group type: OTHER
Intervention: Hydroxychloroquine Sulfate Tablets
Description: Subjects are treated with oral hydroxychloroquine sulfate tablets 200mg twice daily for 20 weeks. All the interventions are built on the guideline-based secondary prevention of coronary heart disease medications.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo Tablets
Description: Subjects are treated with oral placebo tablets 200mg twice daily for 20 weeks. All the interventions are built on the guideline-based secondary prevention of coronary heart disease medications.
Study: NCT04646824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Almonertinib Pemetrexed/Cisplatin
Description: Pemetrexed/Cisplatin Drug: Pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by Almonertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.
Study: NCT01264198

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: Supervised Resistance Training

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Resistance Training
Description: Supervised Resistance Training
Study: NCT03770793

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lung-sono guided
Description: The patient undergoing thoracic surgery is intubated with double lumen tube after induction of general anesthesia with propofol and remifentanil.~In the intervention group, alveolar recruitment is performed to the non-surgical side of lung under examination with ultrasound just after anesthesia induction.~During the gradual increment in the pressure of recruitment, the anesthesiologist can find the opening pressure that means the minimal pressure at which observed atelectasis starts to disappear.~Then, alveolar recruitment is performed with the opening pressure until the atelectasis is not visible.
Study: NCT03033030

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Ultrasound examination